Best Adenoviral Vector CDMOs in Asia

Producer line & serotype

Confirm experience with your serotype (Ad5 and others) and producer cell line, and whether the process is suspension-adapted for scale.

Scale & titer

Adenovirus reaches high titers for vaccine-scale demand. Match validated bioreactor scale to your dose and volume.

Particle quality

Full/empty particle ratio and aggregate control affect potency and safety. Ask about the analytics package.

Regulatory track record

Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.

Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.

Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.

Who are the top Adenoviral Vector CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked Adenoviral Vector CDMOs include CoJourney Inc.. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

What should I look for in an adenoviral vector CDMO?

Confirm serotype and producer-line experience, a suspension process at your required scale, strong particle-quality analytics, and a clean FDA and EMA/MHRA record.

How is adenoviral vector manufacturing different from AAV?

Both are non-enveloped viral vectors made in HEK293-type lines, but adenovirus is larger and drives strong transient expression (suiting vaccines), while AAV is the workhorse for durable in vivo gene therapy.